Cellectis (NASDAQ:CLLS) Posts Earnings Results, Beats Estimates By $0.11 EPS

Cellectis (NASDAQ:CLLS) issued its quarterly earnings results on Friday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.11, Zacks reports. Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%.The firm had revenue of $37.16 million for the quarter, compared to analysts’ expectations of $8.22 million.

Cellectis Price Performance

CLLS traded up $0.06 during trading on Friday, reaching $3.19. 77,515 shares of the stock were exchanged, compared to its average volume of 202,495. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.38 and a quick ratio of 1.38. The company has a market capitalization of $177.30 million, a price-to-earnings ratio of -3.89 and a beta of 3.11. Cellectis has a 1 year low of $1.10 and a 1 year high of $5.48. The business’s 50 day moving average price is $3.39 and its two-hundred day moving average price is $2.42.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Acadian Asset Management LLC lifted its holdings in Cellectis S.A. (NASDAQ:CLLS) by 132.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,377 shares of the biotechnology company’s stock after acquiring an additional 26,461 shares during the period. Acadian Asset Management LLC owned approximately 0.08% of Cellectis worth $55,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Analyst Ratings Changes

CLLS has been the topic of a number of recent research reports. Barclays boosted their target price on Cellectis from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, October 17th. Wall Street Zen raised shares of Cellectis to a “hold” rating in a research note on Saturday, September 20th. Wells Fargo & Company restated a “positive” rating and issued a $4.00 target price on shares of Cellectis in a research note on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $6.00.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.